Interferon, first discovered in 1957, is a substance secreted by cells after infection by viruses or specific bacteria, or upon immune stimulation. The human body can produce a variety of interferons, the commonly used ones are α-interferon, β-interferon and γ-interferon, which regulate the immune system by different mechanisms. It is clear that α and β-interferon have a suppressive effect on the immune system, while γ-interferon has a promotive effect. Currently, β-interferons that can treat multiple sclerosis (MS) include β-interferon 1a and β-interferon 1b. β-interferon has become the first-line drug for relapsing-remitting MS abroad, and it can also be used to treat secondary-remitting MS. β-interferon reduces the total number of clinical relapses in MS, reduces new lesions on MRI and results in a reduction in total lesion volume. 1993 In July 1993, beta-interferon became the first drug approved by the US FDA (Food and Drug Administration) for the treatment of MS. Since its launch, more than 100,000 MS patients have been treated with the drug. in November 1995, it was approved for marketing in Europe and began clinical use in 1996. Currently, one beta-interferon has been approved by our FDA for official clinical application, and the other is in the process of approval.